ATRA Atara Biotherapeutics Inc.

14.06
+0.71  (+5%)
Previous Close 13.35
Open 13.52
Price To Book 3.25
Market Cap 755,836,946
Shares 53,757,962
Volume 877,362
Short Ratio
Av. Daily Volume 886,929

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial data to be presented at ECTRIMS September 11-13, 2019.
ATA188
Multiple sclerosis
BLA filing due 2H 2020. Phase 3 top-line data due prior to filing but will only release data until after acceptance of the BLA filing.
ATA 129 (tab-cel) - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
BLA filing due 1H 2020. Phase 3 top-line data due prior to filing but will only release data until after acceptance of the BLA filing.
ATA 129 (tab-cel) - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 trial ongoing.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting
Phase 1 presentation at ASCO June 4, 2019. ORR 63% in patients who also received chemo + pembrolizumab.
Autologous T Cells
Malignant pleural disease
Phase 2 trial to be initiated 2H 2020.
ATA 129
Epstein-Barr virus + other various cancers

Latest News

  1. Edited Transcript of ATRA earnings conference call or presentation 8-Aug-19 12:00pm GMT
  2. Atara Biotherapeutics, Inc. (ATRA) Q2 2019 Earnings Call Transcript
  3. Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
  4. Analysts Recommend These 2 Falling Knives
  5. Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019
  6. Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering
  7. Atara Biotherapeutics Announces Proposed Offering of Common Stock
  8. Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year
  9. 5 Immunotherapy Stocks to Keep a Close Eye On
  10. Why Atara Biotherapeutics Has Slumped in 2019
  11. Atara Reports Initial Data for Multiple Sclerosis Candidate
  12. Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)
  13. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  14. Were Hedge Funds Right About Flocking Into Atara Biotherapeutics Inc (ATRA) ?
  15. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  16. Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
  17. Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
  18. Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting
  19. Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
  20. Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors